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, and its increasing prevalence promises future growth in DM-related mortality and complications and provides strong motivation to improve the translation of findings from trials into clinical practices (2, 3) . A major barrier to the translation of treatments into practice is lack of evidence describing the extent to which results from clinical trials may be applied to the broader population. It is suspected that adults who participate in clinical trials are younger, healthier, on average, than people seen in most clinical practice settings (4, 5) . This situation is thought to be acute in older adults, who as a group experience more health status heterogeneity compared to younger age groups (6) .
Prior research to examine the external validity of clinical trials has evaluated sociodemographic characteristics or comorbidity counts that may not convey the information most needed to effectively guide clinical decisions. Potential treatment effect modifiers (TEMs) are a subset of multimorbidity indicators that are specific clinical diseases or conditions with a well-described mechanism for treatment effect modification. A different distribution of TEMs, not sociodemographic variables, in the target population than in the trial would raise serious concerns regarding external validity (7, 8) . Selection of people with or without TEMs into trials may be planned, as a result of study inclusion and exclusion criteria (9-11) or unplanned, due to healthy volunteer biases (12, 13) . Therefore, ignoring TEMs in the reporting of clinical trials is a real basis for concerns about their external validity. The presence of TEMs affects the applicability of trials to older adults, making them a priority according to a 2008 National Institute on Aging conference (14) . The prevalence of TEMs is currently unknown in the population of middle-aged (age 45-64 years) or older (age 65+ years) adults with DM.
This study draws upon a United States nationally-representative sample to estimate the prevalence of TEMs among older adults with DM. We illustrate the potential impact of TEMs for reported treatment outcomes in the general population using a simulated trial of a treatment to lower glycosylated hemoglobin (Hb A1c ) in DM. To assess construct validity, we then measure the association of patterns of TEMs with the number of hospitalizations in adults with DM.
METHODS

Population
The U.S. National Health and Nutrition Examination Survey (NHANES) is a nationally-representative study of non-institutionalized civilians designed to study the prevalence of diseases and conditions. Study details are publicly available (15). We joined three survey waves from years 1999-2004 including 8654 individuals aged 45 and older.
Participants were asked "have you ever been told by a doctor or other health professional that you have diabetes or sugar diabetes?" They were also allowed to answer that they had borderline diabetes. People who responded 'borderline' were counted as having DM if they also took insulin or a pill for diabetes, or, suffered from retinopathy, a lower extremity ulcer that took more than 4 weeks to heal or numbness or tingling in the hands or feet due to diabetes. To determine whether under-reporting of DM might substantially affect our results, a sensitivity analysis was conducted to identify individuals who did not report diabetes but met any of the following criteria favoring specificity: fasting glucose >140, non-fasting glucose >200 mg/dL or Hb A1c >7.6. These criteria were deliberately more stringent than usual diagnostic criteria because they were applied only to people who failed to report DM by the main criteria.
TEMs describe a subset of factors that contribute to complex health status in older adults (16) . We examined two categories of TEMs. Physiologic TEMs were defined as factors that contribute to complex health status in adults and were selected from a review of precautions and contraindications (17) of pharmacologic treatment of DM (Table 1) . For continuous variables, groupings were pre-specified as follows. Anemia was defined as a serum hemoglobin <12 g/dL in women and <13 g/dL in men (18) . Congestive heart failure (CHF) was identified through a question asking "has a doctor or other health professional ever told you had congestive heart failure?" High ALT was identified as a high serum alanine aminotransferase (ALT) >40 SI in women and >45 in men. Polypharmacy was defined as taking ≥5 medicines daily, following a previously established cut-point (19) and inspection of prescribed medications and over-thecounter analgesics used daily. Supplements, vitamins and minerals were not counted. Warfarin use was identified. Low GFR was defined as a low glomerular filtration rate (GFR) <60 mm/L calculated using the MDRD equation (20 Reduced ability to engage in physical activity; reduced ability to make health care related appointments Visual impairment
Reduced safety for medications with narrow therapeutic windows such as insulin and sulfonylureas ed dizziness or imbalance lasting ≥2 weeks or for an unknown duration, or, difficulty with falls in the last year were categorized as dizziness. Participants who reported that mental health was "not good" for ≥14 of the past 30 days were categorized as having frequentmental distress in NHANES waves 2001-2004 (22) . Mobility difficulty was defined using self-reported difficulty walking ¼ mile or up 10 steps without equipment (23) . Visual impairment was ascertained as self-reported extreme difficulty reading newsprint or seeing up close in people age 50+ years or examined visual acuity worse than 20/50 in the better eye. Potential confounders included physician visits (≥2 visits last year), gender, education (≥12 years), low income (< $ 20,000 for household) and race (Black). These variables were considered potential confounders based on a priori information regarding their association with DM overall and with hospitalization.
Participants were asked whether they experienced an overnight hospital stay in the last year, other than an emergency room. Those who replied 'yes' were also asked how many times this occurred in the last year. Self-report of this outcome has been shown to agree well with claims (24) .
Statistical Analysis
Analyses were pre-specified and weighted with sampling weights that account for sampling strategy and survey non-response. Differences between subjects with and without DM were compared using either a two-sided t-test with unequal variances or a chi-square test. Binomial Wald 95% confidence intervals are reported. Age categorization groupings were made following convention and after confirming that relatively small numbers above age 85 limited analyses in that group. A pattern analysis was conducted to determine the prevalence of clinically meaningful mutually exclusive combinations of TEMs (25) . For patterns present in >2% of people with DM, we modeled the relative rate of hospitalization in people with DM and the pattern of TEMs compared to people with DM and no TEMs using a multivariable negative binomial regression model. Final models were adjusted for physician visits since gender, education, income and race were not significant predictors after accounting for age, physician visits, DM and TEMs. We report a Bonferroni adjustment to maintain a type I error probability of 0.05 for the set of related tests. Analyses were carried out in Stata version 11 software (26) . Based on initial findings, we also performed an ad hoc analysis of the distribution of age, DM status and high ALT as discussed below.
Drawing from 1249 participants with DM and measured Hb A1c , we simulated a simple trial (27) to examine whether the observed prevalence of TEM patterns could influence estimated treatment effectiveness in a general population. The purpose of the simulation study was to understand the operating characteristics of real-world patterns of potential TEMs under several scenarios. DM participants were randomly placed in a treatment or placebo arm. A treatment lowering Hb A1c by 2 points on average was simulated. We then examined four levels of interaction between TEMs and the simulated treatment, ranging from small to modest (a factor of 0.1, 0.2, 0.3 and 0.4 for each modifier). For example, at the second level of interaction, a person with 2 physiologic TEMs had his or her simulated treatment effect in Hb A1c moving towards null by a factor of (0.2 * 2). We assumed TEMs influenced Hb A1c in the opposite direction as treatment, i.e. interrupting treatment and moving effect towards null, because we examined TEMs based on described mechanisms for blocking the ability to be prescribed or comply with a DM treatment. We assumed that each TEM acted equivalently and that modification was linear. In this way we examined under which conditions the average treatment response would no longer be a lower Hb A1c for subgroups defined by the observed number of TEMs and levels of effect modification.
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RESULTS
Overall NHANES response rates were 76-80% throughout the specified years. Of 8654 participants age 45+, 7883 completed the laboratory examination and 7272 had no missing data on specified covariates and were included in a complete case analysis. A total of 1443 people with DM age 45+ years with sampling weights were representative of approximately 12,333,000 people with DM in the US. People with DM were older, less often White, less highly educated and had lower household income than their counterparts without DM (results not shown).
Compared to middle-aged adults with DM, older adults with DM were more likely to be female, White, have health insurance, have a low income and have access to health care but were less likely to have completed >12 grades of education (Table 2 ). These variables were examined as potential confounders of hospitalization, but after accounting for TEMs only age and access to health care were significantly associated with the outcome and were used in the final models.
Age-stratified prevalence of TEMs was examined among people with DM (Figs. 1a-b) . Relative to adults ages 45 to 64, prevalence of TEMs was higher among individuals who were 65 or older, most notably for polypharmacy and low GFR. High ALT and frequent mental distress were less prevalent in old age. The prevalence of having any 2 or any 3 physiologic or health status TEMs was high, such that 19.0% (95% CI 14.8- 
Example of potential impact by observed prevalence of TEMs on treatment in older adults
A simulated randomized, controlled trial of a treatment lowering Hb A1c by 2% on average was performed (Fig. 2) . At a low level of treatment effect modification there was average benefit, or lowering of Hb A1c , regardless of numbers of TEMs. However, at small or modest levels of effect modification the benefit was cancelled in 3.9-27.2% of older adults with DM. Furthermore, because TEMs are correlated with increasing age, treatment effect was modified with age at an effect modification level of 0.2 or higher (p-value for interaction term =0.001 for 0.2 and <0.001 for 0.3 or 0.4).
Clinical patterns of TEMs among people with DM and association with hospitalization rate
Mutually exclusive clinical patterns of TEMs were examined and those present in >2% of people with DM are shown in Table 3 . Among people with DM, TEMs were absent in 39.0% (95% CI 34.5-43.6) and 37.7% (95% CI 28.9-46.5) for physiologic or health status modifiers, respectively. Most clinical patterns of diabetes and physiologic TEMs were associated with a substantially higher number of hospitalizations. Hospitalization rates within the last year among study participants with DM were greater by a factor of 5.53 (95% CI 3.06-10.0) among people with both CHF and polypharmacy, compared to people with DM but no physiologic TEMs. Fewer patterns of health status treatment effect modifiers were highly prevalent. Adding laboratory-based criteria for DM to account for unreported DM as described in Methods resulted in 111 additional cases of DM. Of the unreported cases, 67.4% were middle-aged adults. Results were not altered consistently, substantively nor significantly by adding unreported DM to the sample (results not shown).
CONCLUSIONS
This study provides insight regarding the prevalence and potential impact on the care of older adults of type 2 diabetes-specific potential treatment effect modifiers (TEMs) -diseases or conditions with the potential to modify the effects of diabetes treatments. The external validity of results from well-performed randomized, controlled clinical trials is jeopardized when trial participants differ from clinically relevant target populations with respect to attributes that modify treatment effect (7, 8) . Drawing from a nationally representative sample of community-dwelling adults, we found potential TEMs were common in older adults with DM, as high as 51% in the case of polyphar- DM: Diabetes Mellitus. *Prevalence among people with DM as % (standard error). These are for mutually exclusive patterns, e.g. DM plus polypharmacy means without any other physiologic TEMs. Totals do not equal 100 in each category due to rare (≤2%) patterns not displayed. **Rate ratio using adults with DM as referent, i.e. incidence rate comparing DM+ pattern of treatment effect modifiers to incidence rate of DM without modifiers. † Adjusted for age and physician visits. ‡ Statistically significant at Bonferroni-adjusted α<0.004. § Prevalence estimates need to be interpreted cautiously in light of relative standard error >0.30. macy. A simple simulation of a randomized, controlled trial with modest levels of treatment effect modification interrupting treatment demonstrated the potential for 3.9-27.2% of older adults with DM to experience no treatment benefit due to the prevalence of these TEMs. Because TEMs are positively correlated with older age, the attenuation of treatment benefit was greater with increasing old age. Although it is useful and important to describe the prevalence of TEMs individually, a person with DM may have several at once. Therefore we examined TEM patterns, taking into account the presence or absence of all TEMs simultaneously. The majority of even middle-aged adults ages 45 and older living with DM were found to have at least one; nearly 1 in 3 middle-aged adults had at least two, TEMs. Several TEM patterns were associated with elevated rates of hospitalization relative to having DM alone.
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By studying TEMs we hope to inspire improvements in reporting, and future design, of trials. Trials report on potential TEMs in their participants irregularly. For example, a review of selection criteria for the UKPDS 33 study demonstrates that the landmark study used CHF, renal function and visual function as exclusion criteria, but it did not report summary statistics for these TEMs nor other TEMs (28) . Unplanned and unexamined selection effects in the trials may be one of the reasons some trials are thought in retrospect to be wrong about treatment effect (29) . Our findings suggest that a simple table reporting the presence of physiologic and health status TEMs across age strata would benefit our understanding of a trial's external validity. We observed that not all potential TEMs are more prevalent in older age: an elevated ALT and frequent mental distress were instead lower. Such findings can occur for a variety of reasons, including survivor effects and the inappropriateness of diagnostic strategies used at younger ages for older adults. It cannot be assumed that all conditions are more prevalent in older age.
These study results may also inform the design of future medium and large size trials of DM using more expansive inclusion criteria. The ability of larger, simple trials to find subgroups within which treatment will work depends on the ability to examine TEMs. Some trials may not make an effort to ensure external validity because of the up-front costs and time required to ensure representation of subgroups. Moreover, there can be debate about how to appropriately account for heterogeneous treatment effects (30) . However, these considerations should be weighed against the benefits that accrue from increasing statistical power by including people at higher risk of the outcome, in addition to the benefit of improved external validity to older adults.
The study findings here should be considered in light of several limitations. Results were limited to potential TEMs chosen primarily for their direct impact on DM treatments and do not include many conditions, such as hearing impairment or urinary symptoms, that may influence adherence (31) . It is also possible that information bias affected these results since people with two chronic diseases may have more contact with health professionals and thus have a third or more diseases identified. This would increase the proportion with two or more, as opposed to one or two, TEMs in our pattern analyses. In addition, in this study some conditions such as CHF were ascertained only via self-report, which can have poor diagnostic accuracy when compared to physiologic testing. For example, a study comparing self-report to structured medical record review in older women with disability found a kappa of 0.48 for CHF (32) . This limitation results from the desire to achieve a representative sample, which entails ascertainment with methods that are not burdensome to participants, do not take a long time and are not prohibitively costly. Another limitation of NHANES is that it does not measure all health status TEMs, such as depression. Given the cross-sectional nature of the data, we cannot tell whether lower estimated prevalence for some diseases at age 65 years and older results from a cohort effect or attrition earlier in life. Our simulation study was simplistic and did not explore a large range of conditions nor complex interactions, rather a small set of conditions chosen on the basis of similarity to real-world conditions. The simulation only focused on those TEMs thought to interrupt treatment. As with all simulations, its validity is uncertain without attempted replication using external data. These analyses are cross-sectional and only general construct validity was assessed, since hospitalization is the result of many factors. The purpose here is to inform the design and reporting of future trials that, by virtue of their focused and experimental design, can directly test for treatment effect modification according to these TEMs as well as according to TEMs that are important regardless of age such as disease severity and adherence.
Based on a nationally-representative survey, we find potential TEMs to be associated with DM and highly prevalent among adults, especially older adults (6) , with DM in the United States. Based on their distribution among people with DM, we estimated through a simple simulation that TEMs have a potential to alter treatment effect in real practice in a substantial number of cases. Several clinical patterns of TEMs were associated with an increased number of hospitalizations. Future trials of DM should consider how to ensure adequate external validity during the design phase, measure and report the presence of TEMs and consider when there is sufficient scientific knowledge to pre-specify hypothesis of treatment effect modification.
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